Providing a diverse range of perspectives from bullish to bearish, 4 analysts have published ratings on Pharming (NASDAQ:PHAR) in the last three months. The following table provides a quick ...
En el siguiente estudio mostramos algunas herramientas que se utilizan para realizar este tipo de ataques fraudulentos en la red, el análisis de estos creadores de fraudes están diseñados para ...
A live webcast and replay of the presentation will be available in the “Upcoming Events” and “News” sections of Pharming’s website. For more information about this conference ...
Hosted on MSN25d
Pharming Group’s Strong Q3 and CEO TransitionPharming Group (PHGUF) has released an update. Pharming Group has reported a strong third quarter in 2024, with total revenues rising by 12% to $74.8 million, driven by growth in its RUCONEST ...
Chief Executive Officer, Sijmen de Vries, commented: “Pharming has delivered an excellent third quarter, increasing quarterly revenues by 12% to a record-high US$74.8 million and also achieving ...
Leiden, the Netherlands, November 5, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming’s management will participate in the following ...
Pharming Group (PHGUF) reports a 12% revenue increase in Q3 2024, driven by Ruconest and Joenja, while navigating operational losses and market expansion efforts. Leiden, the Netherlands, October 10, ...
For more information about this conference, or to schedule a one-to-one meeting with Pharming’s management team, please contact Pharming’s Investor Relations team at [email protected] or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback